Clinical Trial News and Research

RSS

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

24 Jun 2011

EMA CHMP recommends approval of linagliptin for type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes.

24 Jun 2011

Focused ultrasound changes 27 year-old uterine fibroid patient's life

On June 12, 2011, viewers of the CBS Evening News learned about Stephanie Small's gripping story. Suffering from a large uterine fibroid, the 27 year-old was treated last December as part of a MR-guided focused ultrasound clinical trial at the University of Virginia in Charlottesville.

24 Jun 2011

FDA approves second anti-HIV drug from Rutgers-Janssen collaboration

Two decades after Rutgers scientists began working with Paul Janssen, a legendary drug developer and founder of Johnson & Johnson subsidiary Janssen Pharmaceutica, to create new and potent drugs to fight AIDS, the FDA has approved the second anti-HIV drug that came from this collaboration.

24 Jun 2011

Galileo's advanced visual analytics platform to be launched at BIO 2011 conference

Galileo Analytics announced today that it will debut Galileo Cosmos, Galileo's advanced visual analytics platform at the BIO 2011 conference in Washington, DC, providing a powerful new dimension to Galileo's suite of analytical tools and enhancing the company's ability to mine complex sets of de-identified health data.

24 Jun 2011

PCIB reports main results of Amphinex Phase I/II study against multiple cancers

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.

24 Jun 2011

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc Therapeutics, Inc., announced today that it has initiated a Phase IIa, proof of concept (POC), clinical trial with INV-144, a combination drug of losartan with alpha Lipoic Acid (ALA), to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients.

24 Jun 2011

GTRI develops novel iPhone application for patients with Parkinson's

Researchers at the Georgia Tech Research Institute (GTRI) have developed a novel iPhone application that may enable persons with Parkinson's disease and certain other neurological conditions to use the ubiquitous devices to collect data on hand and arm tremors and relay the results to medical personnel.

24 Jun 2011

Clinical trial management systems market to reach over $1.76B by 2017

It is expected that the clinical trial management systems (CTMS) market will achieve a value of $1.76 billion by 2017, according to a new report on companiesandmarkets.com.

24 Jun 2011

Anonymous donor makes generous gift for mesothelioma research

The UH Cancer Center has received a $3.58 million gift from an anonymous donor to support the mesothelioma research of Dr. Michele Carbone, director of the UH Cancer Center. Carbone and colleagues, who include Drs. Haining Yang and Giovanni Gaudino, have made a series of recent scientific breakthroughs that will lead to new ways to prevent and treat the disease

24 Jun 2011

Nature News examines controversy surrounding Indian HPV vaccine trial

After four teenage girls involved in a clinical trial in India testing vaccines for human papillomavirus (HPV) died last year, the study "threatens to have a dual legacy: inflaming unfounded fears about a lifesaving vaccine and raising new questions about the management of medical research in the country," Nature News reports.

24 Jun 2011

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.

24 Jun 2011

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

24 Jun 2011

GeoVax opens third clinical trial site for testing HIV/AIDS vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a third site for testing the therapeutic potential of its HIV/AIDS vaccine.

24 Jun 2011

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan.

24 Jun 2011

Gaining regulatory approval for new medical devices easier than convincing insurers to provide coverage

What's easier: gaining regulatory approval for a new medical device, or convincing insurers to cover the treatments it provides? According to Susan Klees of the Focused Ultrasound Surgery Foundation, many experts say regulatory approval is the easier task.

23 Jun 2011

FDA grants Fast Track designation for Repligen's RG3039 to treat Spinal Muscular Atrophy

Repligen Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RG3039, a potential treatment for Spinal Muscular Atrophy.

23 Jun 2011

Proton beam radiotherapy appears to control breast cancer with minimal side-effects

A treatment that has virtually no side effects has been found to be an effective weapon for fighting early-stage breast cancer, according to results of a clinical trial conducted at Loma Linda University Medical Center.

23 Jun 2011

Positive results from Neurelis NRL-1 Phase I pharmacokinetic study on acute repetitive seizures

In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam achieved positive clinical results in a Phase I pharmacokinetic study.

23 Jun 2011

Telaprevir drug shows promise in curing hepatitis C infection

The drug telaprevir (Incivek) provides a dramatic improvement in the treatment of the most common form of hepatitis C infection, says an international team of investigators led by Dr. Ira M. Jacobson of NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

23 Jun 2011

Clinical Trial News and Research

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

EMA CHMP recommends approval of linagliptin for type 2 diabetes

Focused ultrasound changes 27 year-old uterine fibroid patient's life

FDA approves second anti-HIV drug from Rutgers-Janssen collaboration

Galileo's advanced visual analytics platform to be launched at BIO 2011 conference

PCIB reports main results of Amphinex Phase I/II study against multiple cancers

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

GTRI develops novel iPhone application for patients with Parkinson's

Clinical trial management systems market to reach over $1.76B by 2017

Anonymous donor makes generous gift for mesothelioma research

Nature News examines controversy surrounding Indian HPV vaccine trial

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

GeoVax opens third clinical trial site for testing HIV/AIDS vaccine

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

Gaining regulatory approval for new medical devices easier than convincing insurers to provide coverage

FDA grants Fast Track designation for Repligen's RG3039 to treat Spinal Muscular Atrophy

Proton beam radiotherapy appears to control breast cancer with minimal side-effects

Positive results from Neurelis NRL-1 Phase I pharmacokinetic study on acute repetitive seizures

Telaprevir drug shows promise in curing hepatitis C infection

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer